Canada - français - Health Canada

coralite dental products - extrait d'huile de coton; eugénol; phénol; formocrésol; alcool anhydre; oxyde de zinc; paraformaldéhyde - liquide - 15%; 50%; 9.5%; 45%; 18%; 70%; 2% - extrait d'huile de coton 15%; eugénol 50%; phénol 9.5%; formocrésol 45%; alcool anhydre 18%; oxyde de zinc 70%; paraformaldéhyde 2% - dental agents

Canada - français - Health Canada

coralite dental products - benzocaïne; chlorure de méthyl heptyl colamino formylméthyl pyridinium - pâte - 23%; .1% - benzocaïne 23%; chlorure de méthyl heptyl colamino formylméthyl pyridinium .1% - local anesthetics

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

air products sa-nv - oxygène 100 % v/v - gaz médicinal liquéfié - 100 % v/v - oxygène - oxygen

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

air products sa-nv - oxygène 100 % v/v - gaz médicinal liquéfié - 100 % v/v - oxygène - oxygen

Union européenne - français - EMA (European Medicines Agency)

eli lilly nederland b.v. - mirikizumab - colite ulcéreuse - immunosuppresseurs - omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

iroko products limited - indométacine - suppositoire - 50,000 mg - composition pour un suppositoire > indométacine : 50,000 mg - anti-inflammatoire non steroidien (m muscle et squelette)

Union européenne - français - EMA (European Medicines Agency)

takeda pharma a/s - vedolizumab - colitis, ulcerative; crohn disease - immunosuppresseurs sélectifs - ulcéreuse colitisentyvio est indiqué pour le traitement de patients adultes atteints de modérément à sévèrement active de colite ulcéreuse qui ont eu une réponse inadéquate à, perdu de réponse, ou intolérants soit à la thérapie conventionnelle ou un facteur de nécrose tumorale alpha (tnfa) antagoniste. la maladie de crohn diseaseentyvio est indiqué pour le traitement de patients adultes atteints de modérément à sévèrement active de la maladie de crohn qui ont eu une réponse inadéquate à, perdu de réponse, ou intolérants soit à la thérapie conventionnelle ou un facteur de nécrose tumorale alpha (tnfa) antagoniste. pouchitisentyvio is indicated for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.

Union européenne - français - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - rejet de greffe - immunosuppresseurs - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratorios liconsa s.a. - budésonide 3 mg - gélule à libération modifiée - budesonide

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gedeon richter plc - ethinylestradiol 0,03 mg; drospirénone 3 mg - comprimé pelliculé - 0,03 mg - 3 mg - drospirénone 3 mg; ethinylestradiol 0.03 mg - drospirenone and ethinylestradiol